Business Description
Avenue Therapeutics Inc
NAICS : 325412
SIC : 2833
ISIN : US05360L4032
Total Employee Number:
1Description
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.49 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -61.04 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 76.8 | |||||
3-Year EPS without NRI Growth Rate | 85.3 | |||||
3-Year FCF Growth Rate | 86.9 | |||||
3-Year Book Growth Rate | -78.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 91.69 | |||||
9-Day RSI | 78.94 | |||||
14-Day RSI | 67.63 | |||||
3-1 Month Momentum % | -49.09 | |||||
6-1 Month Momentum % | 38.61 | |||||
12-1 Month Momentum % | -38.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.94 | |||||
Quick Ratio | 1.94 | |||||
Cash Ratio | 1.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -149.29 | |||||
Net Margin % | -124.79 | |||||
EBITDA Margin % | -149.29 | |||||
FCF Margin % | -77.28 | |||||
OCF Margin % | -77.28 | |||||
ROE % | -61.89 | |||||
ROA % | -51.9 | |||||
ROIC % | -1375.33 | |||||
3-Year ROIIC % | -181.15 | |||||
ROCE % | -99.84 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.89 | |||||
PB Ratio | 1.08 | |||||
Price-to-Tangible-Book | 1.08 | |||||
EV-to-EBIT | 0.54 | |||||
EV-to-EBITDA | 0.54 | |||||
EV-to-Revenue | -0.81 | |||||
EV-to-Forward-Revenue | 2.68 | |||||
EV-to-FCF | 1.05 | |||||
| Price-to-Net-Current-Asset-Value | 1.08 | |||||
| Price-to-Net-Cash | 1.11 | |||||
Earnings Yield (Greenblatt) % | 185.19 | |||||
FCF Yield % | -84.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ATXI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Avenue Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.404 | ||
| EPS (TTM) ($) | -0.53 | ||
| Beta | 2.781 | ||
| 3-Year Sharpe Ratio | -0.68 | ||
| 3-Year Sortino Ratio | -0.99 | ||
| Volatility % | 150.71 | ||
| 14-Day RSI | 67.63 | ||
| 14-Day ATR ($) | 0.032773 | ||
| 20-Day SMA ($) | 0.300008 | ||
| 12-1 Month Momentum % | -38.46 | ||
| 52-Week Range ($) | 0.15 - 0.9699 | ||
| Shares Outstanding (Mil) | 3.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Avenue Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Avenue Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-30 10:00 | In 151 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 103 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 12 days | ||
| First quarter earnings results for 2026 | 2026-05-08 | 0.55 (+0.00%) | ||
| Annual report for 2025 | 2026-03-30 | 0.29 (+0.00%) | ||
| General meeting for 2025 | 2025-12-30 10:00 | 0.65 (+0.06%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 0.75 (+0.13%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 0.50 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 0.24 (+33.26%) | ||
| Annual report for 2024 | 2025-03-31 | 0.31 (+1.30%) |
Show
Entries
Avenue Therapeutics Inc Frequently Asked Questions
What is Avenue Therapeutics Inc(ATXI)'s stock price today?
The current price of ATXI is $0.39. The 52 week high of ATXI is $0.97 and 52 week low is $0.15.
When is next earnings date of Avenue Therapeutics Inc(ATXI)?
The next earnings date of Avenue Therapeutics Inc(ATXI) is 2026-08-14 Est..
Does Avenue Therapeutics Inc(ATXI) pay dividends? If so, how much?
Avenue Therapeutics Inc(ATXI) does not pay dividend.
Guru Commentaries on OTCPK:ATXI
No articles.
Press Release
Articles on Avenue Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers